Clair Felpel, DO
Family Medicine · Albany, GANPI 1962849679
Payments from drug & device makers
Across 205 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$559
- Lilly USA, LLC$524
- Novo Nordisk$441
- AstraZeneca$362
- Pfizer$257
- GSK$222
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,813100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 30 | $559 |
| Lilly USA, LLC | 31 | $524 |
| Novo Nordisk | 19 | $441 |
| AstraZeneca | 22 | $362 |
| Pfizer | 13 | $257 |
| GSK | 12 | $222 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $171 |
| Amgen | 8 | $128 |
| Abbott | 7 | $127 |
| Merck | 6 | $115 |
| Viiv Healthcare Company | 5 | $102 |
| Dexcom, Inc. | 4 | $95 |
| Sumitomo Pharma America, Inc. | 4 | $84 |
| Esperion Therapeutics, Inc. | 5 | $83 |
| Astellas Pharma US Inc | 4 | $78 |
| Kowa Pharmaceuticals America, Inc. | 3 | $64 |
| Ardelyx, Inc. | 3 | $60 |
| Boehringer Ingelheim | 3 | $57 |
| Exact Sciences | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Alkermes, Inc. | 2 | $29 |
| Gilead | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Medtronic | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
How this compares
$3,813 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 182 | $229,696 |
| FarxigaDapagliflozin Propanediol | 167 | $151,926 |
| MounjaroTirzepatide | 112 | $142,111 |
| JardianceEmpagliflozin | 138 | $138,786 |
| EliquisApixaban | 120 | $103,019 |
| JanuviaSitagliptin Phosphate | 65 | $70,860 |
| TrulicityDulaglutide | 52 | $70,130 |
| RybelsusSemaglutide | 39 | $58,351 |
| LinzessLinaclotide | 58 | $47,905 |
| KerendiaFinerenone | 31 | $34,280 |
| EntrestoSacubitril/Valsartan | 37 | $32,229 |
| MyrbetriqMirabegron | 41 | $28,028 |
| XareltoRivaroxaban | 22 | $23,912 |
| GemtesaVibegron | 16 | $18,798 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $441 | $288,047221 claims |
| Lilly USA, LLCMounjaro, Trulicity | $524 | $212,241164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $362 | $186,138226 claims |
| Boehringer IngelheimJardiance | $57 | $138,786138 claims |
| PfizerEliquis | $257 | $103,019120 claims |
| MerckJanuvia, Janumet | $115 | $86,79877 claims |
| BayerKerendia | $559 | $34,28031 claims |
| NovartisEntresto | $22 | $32,22937 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $28,02841 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $222 | $27,85350 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $84 | $18,79816 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $2,90342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Albany
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.